Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And off we go! Probably last chance buy in for anyone that has hesitated thus far.
Bottom line the key was to reload on Fridays insane lows. Most of us are already up over 6%. ZYNE will have it's day ahead. The algorithm trades killed us last week or we could have easily ran over $15.00 IMO.
Here is the link for the Cantor Fitz upgrade:
https://www.streetinsider.com/dr/news.php?id=13346899&gfv=1
Also, it appears the value is consolidating at mid $8s. The 5 day chart is showing the downward slope as leveling out between last Friday afternoon and today. Hopefully this the first real sign the shorts are losing control.
It's linked through the stock app I use. I also googled it for a better source and it's appearing on the analyst estimates readout here on InvestorHub.
This hasn't come across Fidelity news. Where are you seeing this? Last upgrade I see is Piper Jaffray to overweight from neutral.
Cantor Fitzgerald just upgraded rating from Neutral to Overweight.
I don't believe this will come down to fill the gap. IMO it will take the same course as MRNS which also gapped up hard then came down to the upper bollie and continued back up.
We're right at the upper bollie now with ZYNE. I believe we should settle in this range for a day or two and start moving gradually up.
Premarket is pretty good right now at 8.76 but it was good the last two trading days as well and couldn't hold it's gains on the open. It's a wait and hold for me.
Yes i added pretty good at 8.60 and hoping the big buyers come to send the short squeeze off like a powder keg!
Just wondering if the shorts can fill that gap before it takes back off. Most gaps fill, but this news seems very good and would think this could turn into a runaway bullish gap. That's why I held and didn't sell the news. Will see. If they fill it, I guess I will count myself lucky enough to buy more in that range. Good luck.
Yes and unfortunately shorts are still in control! When that music stops and big boys cover there blunder this will reverse hard! And continue where it left off before epilepsy. Dec we should here the plan officially from the company. But all is well and as for now has all the cash they need.
That's what I thought when I read the news. I haven't heard such positive results before for any mj based bio tech, but maybe I'm missing something. If this prices as successful as phase two looked, I can't help but think tis legitimizes mj as having real benefits and would force government to remove it from schedule 1.
$ZYNE$ Great update. Thanks for the info. Very helpful.
I have had two meetings with the VP this week. Pre and post news. Discussed all sorts of things going forward! This is news on a global level that i believe only comes a few times in a lifetime.
Right now stuck shorts are in control beating down the price to cover there goof! But long term it means nothing!
AO still is a 75% possibility for a restructured phase 2 Before the end of December along with news of Zyn001 positive phase 1 and initiating ph2. Again Last few weeks of the year.
Talked finance and FXS p3 will only cost about 5-10 million dollars with 100 participants and OA approx 20 million w 300 participants so 30 million needed to secure the approval path!
-70 mill in cash to last till 2019
-Better data then any other spectrum drug in history!
-No debt
-Great management team!
-Orphan drug with 7 years exclusive marketing
-patent protection 2033
-great pipeline
-FDA experience!
What more could anyone possibly ask for?
Hang in there guys! This one goes for platinum!
I thought for sure we would’ve talked today but the days not over yet. If not today, it will be Monday then we should pop hard
Aren't enough catalyst till next year and they know it.
EDGX and NSDQ are literally killing this stock by themselves. They must be real short. They're not going to let this go until they cover.
My TdAmeritrade showing Cancaccord Genuity upgrading the price target from $9 to $15
Need to hold here and go parabolic again or they are not done yet.
I'm guessing the analysts are clueless.
Analyst Actions: Piper Jaffray Upgrades Zynerba Pharmaceuticals to Overweight from Neutral
07:08 AM EDT, 09/29/2017 (MT Newswires) -- Zynerba Pharmaceuticals'(ZYNE) average rating among analysts is a hold, with an average price target of $11.
Price: 9.95, Change: +0.51, Percent Change: +5.40
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
Are analyst updates expected to be published today?
When? Apparently traders didn't get the memo. Lol. Believe me I own a bunch... now at much higher prices and if I didn't have other stocks going up today to offset this non-sense going on with ZYNE I would have let it go for a loss. The constant selling and the spreads they are putting up are scaring away investors who will forget the news by Monday. This almost looks like it's going straight back to where it started.
I just can't see investors selling like this after a successful trial update and the news today about the upgrade. Something else taking it down.
Analyst Actions: Piper Jaffray Upgrades Zynerba Pharmaceuticals to Overweight from Neutral
BY MT Newswires
— 7:08 AM ET 09/29/2017
07:08 AM EDT, 09/29/2017 (MT Newswires) -- Zynerba Pharmaceuticals' ( ZYNE ) average rating among analysts is a hold, with an average price target of $11.
Safe trading tip: If you don't see a strong move up early in the day to maybe ~1pm, it's probably best to get out for the weekend. Just my own personal tactic.
I'll take the 13 for the 2000 I picked up at 9.76 and 15 for the 2000 at 10.55. Lol. Wish I would have waited on those but pre-market looked strong going in.
Yep and another fool put more there. I am betting ZYNE will be up at least to $13.00 to $15.00 in the days ahead and it could be more.
Big money just blasted through 17,345 shares at 10.00.
ARCA just put up 25,000 on ask. need to see if we blast through those as well.
The big money that was in at $20.00 to $25.00 will likely try to take it up to at least $15.00 IMO tomorrow. We will see. They will start in afterhours and pre market trading. Plus we should get upgrades that will help a lot.
ZYNE is at 10.03 in after hours trading. ;)
Bid - 10.00
Ask - 10.09
I agree 100%. On this news ZYNE should be $15.00 to $20.00. Let's see what upgrades do ahead. I would love to see another almost 100% open tomorrow.
I'm expecting a huge bounce tomorrow with upgrades, little disappointed with the late day trading but it is what it is
My lucky day. Sold ZYNE at 12.50 pre-market and bought ROKU at 16.50 on the open. I handed my shares off at 12.50 thinking the 50 EMA at 8.62 would be touched, if not breached to the down side. Sure would be a sweet spot to buy in again there. Maybe tomorrow! Future is bright for ZYNE, longterm this will do very very well.
Shorts are playing a dangerous game here with ZYNE. I think she will run into the close. This news should take us up a few dollars in the trading days ahead. This fall ZYNE should be back over $20.00 IMO However selling a few into the bids since the open has triggered sell algorithm trading. Once it reverses to the upside she will run with buy algorithm trade triggers.
I'm game. Been in and out of ZYNE many times. Was swing trading ZYNE and CARA to 25. I was out of ZYNE for the gap down. A stock doesn't normally gap up 5.00 then drop like this. Seems like it's being shorted to he$$. Every time there's momo huge drops right after. This will eventually go back to 18+. Would at least like to see EOD run to 10.55 min. considering I picked up 2000 more at 9.76.
Exactly. ZYNE could be back over $20.00 in no time ahead on the charts. Insiders loaded there this past year so they think we will be higher again and we were over $25.00 in April ahead of these positive results.
Agree. These prices are a steal. Well funded, tons of insider buys $15-20 , insanely low SS and positive clinical trials on an Orphan CBD drug. Entourage Effect happening in the Cannabis bio-pharma space.
I am holding ZYNE is a great investment now.
They shorted big-time this morning and killed the run. Now I'm watching to see how the day closes. But if it drops anymore, I'm getting out.
9.51 9.52 bottom? Double bottom there on the intraday. Picked up 2000 pre-market at 10.55. Thinking about adding 2000 more here at 9.70's but the decline seems endless. Just broke PSAR. Hit over 13.00 pre-market. Was expecting a dip after open but nothing like this. This really needs to hit 9.95 to break out again.
Anyone have any input. Fidelity daily showing no resistance because of that huge gap down in August.
I just sold one of my other Stocks and I'm getting ready to put that money into ZYNE
Followers
|
91
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2676
|
Created
|
08/06/15
|
Type
|
Free
|
Moderators |
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.
Corporate Profile |
Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016.
ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.
In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.
EPS (TTM) | 9/30/2016 | -2.47 |
---|---|
P/E Ratio | 9/30/2016 | -- |
Market Cap | Micro Cap | 146M |
Shares Outstanding | 9.95M |
Float | 7.2M |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |